Semax and Selank are both synthetic neuropeptides developed in Russia with ACTH-derived sequences. They appear in research literature under similar categories — nootropic, anxiolytic, neuroprotective — but their mechanisms and primary research applications are distinct. This comparison covers what the preclinical and early clinical literature shows about each.
Origins and Structure
Semax is a heptapeptide derived from the ACTH(4-10) fragment. The sequence Met-Glu-His-Phe-Pro-Gly-Pro gives it melanocortin receptor affinity without the full hormonal activity of ACTH. It was developed by the Russian Academy of Sciences and has been used in Russian hospitals as a nootropic and neuroprotective agent since the 1990s.
Selank is also a heptapeptide, derived from the endogenous immunomodulatory peptide Tuftsin (Thr-Lys-Pro-Arg) with an additional tripeptide extension. Its structure was designed to improve CNS penetration and stability compared to native Tuftsin.
Mechanisms: Where They Differ
Semax increases BDNF and NGF expression in the hippocampus and prefrontal cortex in rodent studies. It modulates dopamine and serotonin systems and has been examined in neuroprotection models — particularly ischaemic stroke, where rodent studies showed reduced infarct size and preserved cognitive function.
Selank modulates GABAergic transmission and increases BDNF expression through a different receptor profile. Unlike benzodiazepines, it shows anxiolytic effects in rodent models without apparent sedation or dependence. Studies have also examined its effects on the kynurenine pathway and immune cytokine profiles — an angle absent from the Semax literature.
Primary Research Applications
Semax is studied most for cognitive enhancement under stress, neuroprotection following ischaemic events, and BDNF/NGF pathway modulation. It appears in more neurological and neuroregenerative research contexts.
Selank is studied primarily as an anxiolytic and stress-response modulator. Its immunomodulatory properties — effects on IL-6, TNF-alpha, and the kynurenine pathway — distinguish it from Semax and represent a research angle unique to the Selank literature.
Comparing the Research Evidence
Semax has more extensive published literature, including limited human studies conducted in Russia on stroke patients and cognitive performance. Selank’s human research is narrower but includes some Russian clinical data on anxiety and stress markers. Both lack large-scale randomised controlled trials meeting Western regulatory standards.
Which to Choose for Research
The choice depends on the research question. For neuroprotection, BDNF pathway studies, or cognitive models under acute stress, Semax is the more documented choice. For anxiolytic mechanisms, GABAergic modulation, or immune-CNS interaction research, Selank’s distinct profile is more relevant. Some researchers study both to compare receptor overlap and distinct pathway contributions.
FenaLife supplies Semax 10mg and Selank 10mg, each independently tested by Janoshik Analytical. View COAs here.
Frequently Asked Questions
Can Semax and Selank be studied together?
Yes. Some researchers examine them in combination to study additive or complementary effects on BDNF expression and stress response. No negative interactions have been reported in the preclinical literature.
Which has more clinical evidence?
Semax has more published clinical data, primarily from Russian studies on stroke recovery and cognitive performance. Both lack large Western-standard RCTs.
Are these approved for human use?
Semax has regulatory approval in Russia for certain indications. Neither is approved by the FDA or EMA. Both are sold here for research use only.
For research use only. Not for human consumption, injection, or ingestion.